News Releases

January 11, 2021
Synlogic Outlines Upcoming Clinical Milestones
- Clinical proof of concept data in 2021 anticipated across multiple programs - CAMBRIDGE, Mass. , Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined significant clinical...
December 14, 2020
Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma
- SYNB1891 demonstrates STING activation and target engagement in the tumor microenvironment in monotherapy cohorts - CAMBRIDGE, Mass. , Dec. 14, 2020 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine,...
December 9, 2020
Synlogic Appoints Michael Heffernan to its Board of Directors
CAMBRIDGE, Mass. , Dec. 9, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Michael Heffernan to its board of directors....
December 7, 2020
Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome Engineering
CAMBRIDGE, Mass. , Dec. 7, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present additional translational and in silico data on SYNB8802, a Synthetic Biotic medicine...
November 18, 2020
Synlogic to Present at Upcoming Virtual Banking Conference
CAMBRIDGE, Mass. , Nov. 18, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of...
November 5, 2020
Synlogic Reports Third Quarter 2020 Financial Results and Provides Business Update
- Synlogic ends 3Q2020 with $102.0 million in cash, cash equivalents and investments supporting projected runway into 2022 -   - Phase 2 study of SYNB1618 and Phase 1 study of SYNB8802 initiated -   - Management to host conference call and webcast at 8:30 a.m. ET today - CAMBRIDGE, Mass. , Nov....
November 4, 2020
Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric Hyperoxaluria
CAMBRIDGE, Mass. , Nov. 4, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced it has treated the first healthy volunteer in its Phase 1 study of the investigational Synthetic Biotic...
October 27, 2020
Synlogic Announces Third Quarter 2020 Conference Call & Webcast
CAMBRIDGE, Mass. , Oct. 27, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its third quarter 2020 financial results before the market opens on Thursday,...
October 22, 2020
Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020
CAMBRIDGE, Mass. , Oct. 22, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present a poster on SYNB8802, an investigational Synthetic Biotic medicine for the treatment...
September 14, 2020
Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass. , Sept. 14, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of David Hava , Ph.D. as Chief Scientific Officer. Dr....
September 8, 2020
Synlogic to Present at Upcoming Virtual Banking Conferences
CAMBRIDGE, Mass. , Sept. 8, 2020 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's president and chief executive officer, and other members of...
August 6, 2020
Synlogic Reports Second Quarter 2020 Financial Results and Provides Business Update
- Synlogic ends 2Q2020 with $109.1 million in cash, cash equivalents and investments supporting projected runway into 2022 - Company continues to advance multiple clinical stage Synthetic Biotic medicines - Management to host conference call and webcast at 8:00 am ET today - CAMBRIDGE,...
Displaying 1 - 12 of 124